CDT
CDT Equity Inc.Healthcare · $37K market cap
Verdict
We can't put a fair value on CDT right now. The financial data we receive for it contains an obvious error (its equity or assets jump more than 100× in one year). We'll value it once the data is corrected.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow CDT
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Jul 30, 2026: no open-market purchases, 1 sale worth $0 and 3 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
About CDT Equity Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works